Published in Afr J Tradit Complement Altern Med on July 03, 2010
A survey of complementary and alternative medicine use in cancer patients treated with radiotherapy in Thailand. Evid Based Complement Alternat Med (2012) 0.91
Use of chinese herb medicine in cancer patients: a survey in southwestern china. Evid Based Complement Alternat Med (2012) 0.85
Pharmacogenomics and herb-drug interactions: merge of future and tradition. Evid Based Complement Alternat Med (2015) 0.83
Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro. BMC Complement Altern Med (2015) 0.75
HERBAL PRODUCT USE BY THE CANCER PATIENTS IN BOTH THE PRE AND POST SURGERY PERIODS AND DURING CHEMOTHERAPY. Afr J Tradit Complement Altern Med (2017) 0.75
Spiritual Therapy in Coping with Cancer as a Complementary Medical Preventive Practice. J Cancer Prev (2017) 0.75
Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol (2000) 5.48
The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer (1998) 4.95
Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum (2000) 2.41
Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med (2002) 1.85
Use of complementary and alternative medicine by chinese women with breast cancer. Breast Cancer Res Treat (2004) 1.76
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med (2008) 1.51
Use of unconventional therapies by children with cancer at an urban medical center. J Pediatr Hematol Oncol (2000) 1.46
Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Williston Park) (2001) 1.17
Surveys of complementary and alternative medicine: Part II. Use of alternative and complementary cancer therapies. J Altern Complement Med (2001) 1.16
Alternative medicine use worldwide: the International Union Against Cancer survey. Cancer (2001) 1.03
Complementary cancer treatments: hope or hazard? Clin Oncol (R Coll Radiol) (1995) 1.02
The use of complementary and alternative medicine among Chinese Canadians: results from a national survey. J Immigr Minor Health (2008) 0.94
Complementary medicine in the primary care setting: Results of a survey of gender and cultural patterns in Israel. Gend Med (2009) 0.94
Which medicine? Whose standard? Critical reflections on medical integration in China. J Med Ethics (2007) 0.89
The use of complementary medications by cancer patients attending an outpatient pain and symptom clinic. J Palliat Care (1998) 0.85
'Thinking outside the box': complementary and alternative therapies use in paediatric oncology patients. Eur J Oncol Nurs (2004) 0.82
Quality of life and patterns of nontraditional therapy use by patients with cancer. Oncol Nurs Forum (2001) 0.81
A broadly conserved pathway generates 3'UTR-directed primary piRNAs. Curr Biol (2009) 2.69
Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood (2003) 1.93
Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol (2010) 1.64
Molecular mechanisms of germline stem cell regulation. Annu Rev Genet (2005) 1.52
A role for MEIS1 in MLL-fusion gene leukemia. Blood (2008) 1.52
Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. Blood (2002) 1.27
Extranodal follicular dendritic cell sarcoma in mesentery: A case report. Oncol Lett (2011) 1.01
Characterization and promoter analysis of the mouse nestin gene. FEBS Lett (2004) 1.01
Single nanoparticle detection using photonic crystal enhanced microscopy. Analyst (2014) 1.00
Modeling human infant MLL leukemia in mice: leukemia from fetal liver differs from that originating in postnatal marrow. Blood (2011) 0.95
Ectopic expression of the Drosophila Cdk1 inhibitory kinases, Wee1 and Myt1, interferes with the second mitotic wave and disrupts pattern formation during eye development. Genetics (2002) 0.94
Natural variation of the amino-terminal glutamine-rich domain in Drosophila argonaute2 is not associated with developmental defects. PLoS One (2010) 0.94
Surgical management of retrorectal tumors: a retrospective study of a 9-year experience in a single institution. Onco Targets Ther (2011) 0.93
Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Mol Oncol (2013) 0.91
Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One (2011) 0.90
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther (2012) 0.89
Surgical treatment of retrorectal tumors: a retrospective study of a ten-year experience in three institutions. Hepatogastroenterology (2012) 0.88
High-level expression, purification, and characterization of recombinant human basic fibroblast growth factor in Pichia pastoris. Protein Expr Purif (2008) 0.87
Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection. Hepatogastroenterology (2011) 0.86
Mammotome(®) biopsy system for the resection of breast lesions: Clinical experience in two high-volume teaching hospitals. Exp Ther Med (2013) 0.85
Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it. Clin Transl Oncol (2011) 0.85
Laparoscopic gastrectomy for gastric cancer in China: an overview. Hepatogastroenterology (2015) 0.85
Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? Hepatogastroenterology (2011) 0.85
Protease-activated receptors in cancer: A systematic review. Oncol Lett (2011) 0.85
XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One (2012) 0.84
Synchronous primary carcinomas of the rectum and prostate: Report of three cases. Oncol Lett (2011) 0.84
Safety and efficacy of holmium laser resection for primary nonmuscle-invasive bladder cancer versus transurethral electroresection: single-center experience. Urology (2008) 0.84
Learning curve for endoscopic thyroidectomy: a single teaching hospital study. Onco Targets Ther (2013) 0.84
Stabilization of speckle-type POZ protein (Spop) by Daz interacting protein 1 (Dzip1) is essential for Gli turnover and the proper output of Hedgehog signaling. J Biol Chem (2013) 0.83
Estrogen-independent effects of ER-α36 in ER-negative breast cancer. Steroids (2012) 0.83
Retroperitoneal primary mucinous adenocarcinoma: A case report. Oncol Lett (2011) 0.83
Syringocystadenoma papilliferum in the right lower abdomen: a case report and review of literature. Onco Targets Ther (2013) 0.83
Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol (2010) 0.82
Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Int J Oncol (2012) 0.81
Minimally invasive esophagectomy for esophageal cancer in the People's Republic of China: an overview. Onco Targets Ther (2013) 0.81
Maternal Dead-End1 is required for vegetal cortical microtubule assembly during Xenopus axis specification. Development (2013) 0.81
Transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a retrospective study of a 5-year experience in a single institution. Hepatogastroenterology (2013) 0.80
Heterogeneity between primary colon carcinoma and paired lymphatic and hepatic metastases. Mol Med Rep (2012) 0.80
Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism. Oncol Lett (2012) 0.79
Synchronous bilateral Paget's disease of the breast: A case report. Oncol Lett (2012) 0.78
Using theory and evidence to drive measurement of patient, nurse and organizational outcomes of professional nursing practice. Int J Nurs Pract (2013) 0.78
Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. Int J Mol Med (2012) 0.78
Protein-protein binding detection with nanoparticle photonic crystal enhanced microscopy (NP-PCEM). Conf Proc IEEE Eng Med Biol Soc (2014) 0.77
Mathematical model for two germline stem cells competing for niche occupancy. Bull Math Biol (2012) 0.77
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. Cancer Biol Ther (2012) 0.77
Antitumor effect of FP3 on a patient-derived tumor tissue xenograft model of rectal carcinoma. Hepatogastroenterology (2014) 0.77
First intron of nestin gene regulates its expression during C2C12 myoblast differentiation. Acta Biochim Biophys Sin (Shanghai) (2008) 0.77
FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects. Hepatogastroenterology (2013) 0.76
COLORECTAL Polymeric Immunoglobulin Receptor Expression is Correlated with Hepatic Metastasis and Poor Prognosis in Colon Carcinoma Patients with Hepatic Metastasis. Hepatogastroenterology (2014) 0.76
Antitumor effect of FP3 in a breast cancer xenograft model. Exp Ther Med (2012) 0.76
Heterogeneity-related anticancer therapy response differences in metastatic colon carcinoma: new hints to tumor-site-based personalized cancer therapy. Hepatogastroenterology (2014) 0.75
Short- and long-term outcomes after conversion of laparoscopic total gastrectomy for gastric cancer: a single-center study. J BUON (2017) 0.75
Anti-angiogenic therapy for colorectal cancer: on the way to getting better! Hepatogastroenterology (2012) 0.75
Totally Laparoscopic D2 Radical Distal Gastrectomy Using Delta-Shaped Anastomosis: Initial Experience. Hepatogastroenterology (2015) 0.75
Mobile platform for multiplexed detection and differentiation of disease-specific nucleic acid sequences, using microfluidic loop-mediated isothermal amplification and smartphone detection. Anal Chem (2017) 0.75
Totally laparoscopic right colectomy: technique description. Hepatogastroenterology (2015) 0.75